Latest News & Features
Big Pharma
GSK subsidiary and Exavir Therapeutics end dispute over licensing rights for HIV-drug compounds | Resolution follows allegations that Exavir's actions disrupted ViiV Healthcare's research collaboration with a US university. 25 April 2024
%20at%20IP%20firm%20Mewburn%20Ellis.jpg/r%5Bwidth%5D=1280&r%5Bheight%5D=720/4e51dc50-031c-11ef-9bd6-93566cb3a995-Katherine%20Collins%2C%20Associate%2C%20Patent%20Attorney%20(Life%20Sciences)%20at%20IP%20firm%20Mewburn%20Ellis.webp)
Biotechnology
Improving patient access is a UN goal but for companies transitioning from trials to full-scale production, IP is essential, explains Katherine Collins of Mewburn Ellis. 25 April 2024
Biotechnology
UK High Court invalidates two patents due to “overwhelming evidence” supplied by defendant | Biotech firm files same claims in Netherlands division of UPC on same day. 25 April 2024
Biotechnology
Vanda denied opportunity to revive patents for its sleep-disorder drug in dispute against Teva | Decision also rejects revisiting the 2007 case, KSR International v Teleflex, concerning the issue of obviousness in patent claims. 23 April 2024
Biotechnology
Opposition Division upholds patent challenged by 'straw men' | Dutch biotech has seen off challenges to patents in Europe and Japan. 23 April 2024
Medtech
Medtech moved more than $1 billion in income from its US operations to a Caribbean island | New twist in long-running transfer pricing dispute between company and the IRS over ‘arm's-length’ royalty owed under intercompany licences. 18 April 2024
Biotechnology
As artificial intelligence creates a complex legal landscape for healthcare and medtech, Janine Swarbrick of HSF explores two case studies that shed light on how to claim an AI invention. 18 April 2024
Careers
Ex-head of Kramer Levin life sciences practice leaves for new firm | 20 years of experience includes numerous multi-billion dollar cases for some of the world’s best-selling drugs. 16 April 2024
Big Pharma
Judges determine six claims of Novarad’s AR patent to be unpatentable but uphold a further claim | Decision follows unsuccessful challenge by Medivis to another Novarad patent in March. 16 April 2024
Biotechnology
A US District Court has granted a motion to stay the company’s lawsuit against Pfizer and BioNTech | Decision pauses proceedings until two inter partes review proceedings are resolved. 16 April 2024